Rafael Alonso Fernandez
Overview
Explore the profile of Rafael Alonso Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lakhwani S, Mateos M, Martinez-Lopez J, Paiva B, Rosinol Dachs L, Martinez R, et al.
Ann Hematol
. 2024 Oct;
103(12):5651-5661.
PMID: 39438321
Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact...
2.
Ayala R, Alonso Fernandez R, Garcia-Gutierrez V, Alvarez-Larran A, Osorio S, Sanchez-Pina J, et al.
EJHaem
. 2023 May;
4(2):401-409.
PMID: 37206258
This phase Ib, non-randomized, open-label study evaluates the safety and tolerability of ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib-resistant myelofibrosis (MF). A total of...
3.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, et al.
Clin Cancer Res
. 2022 Oct;
29(1):279-288.
PMID: 36282272
Purpose: Proteasome inhibitors (PI) are the backbone of various treatment regimens in multiple myeloma. We recently described the first in-patient point mutations affecting the 20S subunit PSMB5 underlying PI resistance....
4.
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
Alonso Fernandez R, Encinas Mayoral J, Pierre-Louis L, Yao Y, Xu Y, Mu S, et al.
Blood Adv
. 2022 Jul;
7(1):9-19.
PMID: 35882498
Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that enables tumor development. One of the mechanisms of immune evasion used by MM cells is the inhibition of natural killer...
5.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, et al.
Blood
. 2021 Jun;
138(18):1721-1726.
PMID: 34115836
Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent hematologic malignancy. Patients respond well to...